With a paucity of venture capital firms willing to invest in medtech companies, strategic players are being called upon to assume larger, more active roles in the process of starting and funding the start-ups that they may someday acquire.
Medtech entrepreneurs and investors look at their biopharmaceutical counterparts with envy. In that sector, venture capitalists and strategic acquirers operate...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?